Related Experiment Videos
Lipid-based amphotericin B for the treatment of fungal infections
1Department of Pharmacy, Virginia Commonwealth University, Richmond 23298-0533, USA.
Abstract:
The frequency of life-threatening fungal infections has increased dramatically over the past few decades. For more than 30 years amphotericin B has been the standard treatment for systemic and deep-seated fungal infections, primarily because of its broad spectrum of activity. Its usefulness is limited by a relatively high frequency of significant adverse events including infusion-related reactions and nephrotoxicity. In an effort to overcome these side effects, a number of lipid-based formulations were developed, each with its own composition and pharmacokinetic behavior. The clinical significance of these differences is unknown. Available clinical data suggest the formulations have a reduced propensity for causing nephrotoxicity. However, considering limited efficacy data, they should be reserved as second-line therapy for patients who cannot tolerate or fail an adequate trial of conventional amphotericin B or cannot benefit from other antifungal agents.
Insights
Lipid formulations of amphotericin B reduce kidney toxicity in fungal infections. However, due to limited efficacy data, they are recommended as second-line treatments for patients intolerant to conventional amphotericin B.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Life-threatening fungal infections are increasing.
- Amphotericin B is the standard treatment but causes significant adverse events like nephrotoxicity.
- Lipid-based amphotericin B formulations were developed to mitigate side effects.
Purpose of the Study:
- To evaluate the clinical significance of differences among lipid-based amphotericin B formulations.
- To assess the safety and efficacy of these formulations compared to conventional amphotericin B.
Main Methods:
- Review of available clinical data on lipid-based amphotericin B formulations.
- Comparison of adverse event profiles, particularly nephrotoxicity.
- Assessment of efficacy data for systemic and deep-seated fungal infections.
Main Results:
- Lipid formulations appear to have a reduced propensity for causing nephrotoxicity.
- Clinical data on the efficacy of these formulations are limited.
- Differences in composition and pharmacokinetics among formulations are not fully understood in terms of clinical significance.
Conclusions:
- Lipid-based amphotericin B formulations show promise in reducing nephrotoxicity.
- Due to limited efficacy data, these formulations should be reserved for specific patient populations.
- Consideration as second-line therapy for patients failing or intolerant to conventional amphotericin B or other antifungals is recommended.